A phase Ib/II study of cancer stem cell inhibitor BBI608 administered with panitumumab in KRAS wild-type (wt) patients (pts) with metastatic colorectal cancer (mCRC) following progression on anti-EGFR therapy

被引：3
作者：
Ciombor, Kristen Keon
Edenfield, William Jeffery
Hubbard, Joleen Marie
O'Dwyer, Peter J.
Becerra, Carlos
Larson, Tim
Spira, Alexander I.
Grothey, Axel
Manoharan, Divya
Li, Wei
Li, Youzhi
Borodyansky, Laura
Li, Chiang
Bekaii-Saab, Tanios S.
机构：
[1] Ohio State Univ Wexner Med Ctr, Columbus, OH USA
[2] Univ Med Ctr, Greenville Hosp Syst, Inst Translat Oncol Res, Greenville, SC USA
[3] Mayo Clin, Rochester, MN USA
[4] Hosp Univ Penn, Philadelphia, PA 19104 USA
[5] US Oncol Res, TOPS Phase Program 1, Dallas, TX USA
[6] US Oncol Res, TOPS Phase Program 1, Minneapolis, MN USA
[7] US Oncol Res, Virginia Canc Specialists Res Inst, Fairfax, VA USA
[8] Boston Biomed Inc, Cambridge, MA USA
[9] Ohio State Univ Comprehens Canc Ctr, Columbus, OH USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.3617
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3617
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Treatment for RAS wild-type (wt) metastatic colorectal cancer (mCRC): Continuation of anti-EGFR therapy while switching chemotherapy regimen.
    Vladimirova, Liubov Yu
    Abramova, Natalya A.
    Kit, Oleg Ivanovich
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [32] SPIRITT (study 20060141): A randomized phase II study of FOLFIRI with either panitumumab (pmab) or bevacizumab (bev) as second -line treatment (tx) in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC).
    Hecht, J. Randolph
    Cohn, Allen Lee
    Dakhil, Shaker R.
    Saleh, Mansoor N.
    Piperdi, Bilal
    Cline-Burkhardt, Vivian Jean M.
    Tian, Ying
    Go, William Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [33] Phase II study of FOLFOXIRI plus panitumumab (pmab) followed by evaluation for resection, in patients (pts) with metastatic KRAS wild-type colorectal cancer (mCRC) with liver metastases only.
    Zakari, Ahmed
    Gian, Victor G.
    Meluch, Anthony Alan
    Peyton, James D.
    Waterhouse, David Michael
    Lipman, Andrew J.
    Boccia, Ralph V.
    Jones, Suzanne Fields
    Bendell, Johanna C.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [34] Phase Ib study of cancer stem cell (CSC) pathway inhibitor BBI-608 administered in combination with FOLFIRI with and without bevacizumab (Bev) in patients (pts) with advanced colorectal cancer (CRC).
    Hubbard, Joleen Marie
    O'Neil, Bert H.
    Jonker, Derek J.
    Halfdanarson, Thorvardur Ragnar
    Starodub, Alexander
    Grothey, Axel
    Borodyansky, Laura
    Li, Chiang
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [35] A phase I/II study of panitumumab combined with TAS-102 in patients (pts) with RAS wild-type (wt) metastatic colorectal cancer (mCRC) refractory to standard chemotherapy: APOLLON study
    Yamazaki, K.
    Yasui, H.
    Yamaguchi, K.
    Kagawa, Y.
    Kuboki, Y.
    Yoshino, T.
    Gamoh, M.
    Komatsu, Y.
    Satake, H.
    Goto, M.
    Tanioka, H.
    Oki, E.
    Kotaka, M.
    Makiyama, A.
    Denda, T.
    Soeda, J.
    Shibya, K.
    Iwata, M.
    Oba, K.
    Kato, T.
    ANNALS OF ONCOLOGY, 2018, 29
  • [36] Genomic markers of panitumumab resistance including ERBB2/HER2 in a phase II study of KRAS wild-type (wt) metastatic colorectal cancer (mCRC).
    Barry, Garrett
    Li-Chang, Hector Hugo
    Kennecke, Hagen F.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [37] SPIRITT (study 20060141): A randomized phase II study of FOLFIRI with either panitumumab (pmab) or bevacizumab (bev) as second-line treatment (tx) in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC)
    Cohn, Allen Lee
    Hecht, J. Randolph
    Dakhil, Shaker
    Saleh, Mansoor N.
    Piperdi, Bilal
    Cline-Burkhardt, Vivian Jean M.
    Tian, Ying
    Go, William Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [38] Genomic markers of panitumumab resistance including ERBB2/HER2 in a phase II study of KRAS wild-type (wt) metastatic colorectal cancer (mCRC)
    Barry, Garrett S.
    Cheang, Maggie C.
    Chang, Hector Li
    Kennecke, Hagen F.
    ONCOTARGET, 2016, 7 (14) : 18953 - 18964
  • [39] Dissecting primary resistance to anti-EGFR monoclonal antibodies (anti-EGFRs) in RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC)
    Cremolini, Chiara
    Berenato, Rosa
    Morano, Federica
    Moretto, Roberto
    Perrone, Federica
    Tamborini, Elena
    Rossini, Daniele
    Gloghini, Annunziata
    Busico, Adele
    Fuca, Giovanni
    Baratelli, Chiara
    Tamburini, Emiliano
    Capone, Iolanda
    Volpi, Chiara Costanza
    Milione, Massimo
    Di Maio, Massimo
    Fontanini, Gabriella
    De Braud, Filippo
    Falcone, Alfredo
    Pietrantonio, Filippo
    CANCER RESEARCH, 2017, 77
  • [40] A randomized, phase Ib/II trial of rilotumumab (AMG 102; ril) or ganitumab (AMG 479; gan) with panitumumab (pmab) versus pmab alone in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC): Primary and biomarker analyses
    Eng, C.
    Van Cutsem, E.
    Nowara, E.
    Swieboda-Sadlej, A.
    Tebbutt, N. C.
    Mitchell, E. P.
    Davidenko, I.
    Oliner, K.
    Chen, L.
    Huang, J.
    McCaffery, I.
    Loh, E.
    Smethurst, D.
    Tabernero, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345